Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Denali Therapeutics Inc. | d463296dex322.htm |
| EX-32.1 - EX-32.1 - Denali Therapeutics Inc. | d463296dex321.htm |
| EX-31.2 - EX-31.2 - Denali Therapeutics Inc. | d463296dex312.htm |
| EX-31.1 - EX-31.1 - Denali Therapeutics Inc. | d463296dex311.htm |
| EX-10.18 - EX-10.18 - Denali Therapeutics Inc. | d463296dex1018.htm |
| EX-10.17 - EX-10.17 - Denali Therapeutics Inc. | d463296dex1017.htm |
| EX-10.16 - EX-10.16 - Denali Therapeutics Inc. | d463296dex1016.htm |
| EX-10.12.1 - EX-10.12.1 - Denali Therapeutics Inc. | d463296dex10121.htm |
| 10-K - FORM 10-K - Denali Therapeutics Inc. | d463296d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-221946) pertaining to the 2017 Equity Incentive Plan, the 2017 Employee Stock Purchase Plan and the 2015 Stock Incentive Plan of Denali Therapeutics Inc. of our report dated March 19, 2018, with respect to the consolidated financial statements of Denali Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Redwood City, California
March 19, 2018